Feedback
Settings

Settings

1. WO2008149110 - BICYCLOR [2.2.1] HEPT-7-YLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES AND CONDITIONS IN WHICH M3 MUSCARINIC RECEPTOR ACTIVITY AND BETA-ADRENERGIC ACTIVITY ARE IMPLICATED

PermaLink
Publication Number WO/2008/149110
Publication Date 11.12.2008
International Application No. PCT/GB2008/001955
International Filing Date 06.06.2008
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
405
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
409
Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
14
containing three or more hetero rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425
Thiazoles
428
condensed with carbocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
4704
2-Quinolinones, e.g. carbostyril
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
535
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
536
ortho- or peri-condensed with carbocyclic ring systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1
Drugs for disorders of the alimentary tract or the digestive system
04
for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29
Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
C07D 405/12 (2006.01)
C07D 409/12 (2006.01)
C07D 413/12 (2006.01)
C07D 417/12 (2006.01)
C07D 417/14 (2006.01)
A61K 31/428 (2006.01)
CPC
C07D 405/12
C07D 409/12
C07D 413/12
C07D 417/12
C07D 417/14
Applicants
  • ARGENTA DISCOVERY LIMITED [GB/GB]; 8/9 Spire Green Centre Flex Meadow Harlow Essex CM19 5TR, GB (AllExceptUS)
  • ASTRAZENECA AB [SE/SE]; S-151 85 Sodertalje, SE (AllExceptUS)
  • ALCARAZ, Lilian [FR/GB]; GB (UsOnly)
  • KINDON, Nicholas [GB/GB]; GB (UsOnly)
  • SUTTON, Jonathan, Mark [GB/GB]; GB (UsOnly)
Inventors
  • ALCARAZ, Lilian; GB
  • KINDON, Nicholas; GB
  • SUTTON, Jonathan, Mark; GB
Agents
  • MERCER, Christopher, Paul ; Carpmaels & Ransford 43-45 Bloomsbury Square London WC1A 2RA, GB
Priority Data
0711085.108.06.2007GB
0711086.908.06.2007GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BICYCLOR [2.2.1] HEPT-7-YLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES AND CONDITIONS IN WHICH M3 MUSCARINIC RECEPTOR ACTIVITY AND BETA-ADRENERGIC ACTIVITY ARE IMPLICATED
(FR) DÉRIVÉS DE BICYCLOR [2.2.1] HEPT-7-YLAMINE ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES ET D'ÉTATS PATHOLOGIQUES DANS LESQUELS EST IMPLIQUÉE L'ACTIVITÉ DES RÉCEPTEURS MUSCARINIQUE M3 ET BÊTA-ADRÉNERGIQUE
front page image
Abstract
(EN)
The present invention relates to compounds of formula (I) having muscarinic M3 receptor and β-adrenergic receptor modulating activity; wherein R1, R2, R3 and X are as defined herein.
(FR)
La présente invention concerne des composés de formule (I) qui exercent une activité modulante vis à vis des récepteurs muscarinique M3 et β-adrénergique; R1, R2, R3 et X sont tels que définis ici.
Latest bibliographic data on file with the International Bureau
# -